Aimwell Partners Inc. reports company developments centered on AimwellBio, its healthcare and biopharmaceutical intelligence business. Recurring announcements cover the rollout of AIMWELL Cortex, the Federated Health Intelligence Network, source-traceable signal monitoring, confidence scoring, and verification processes designed for clinical, research, regulatory, and biopharma users.
Company news also describes demonstrations, onboarding activity, founding cohort development, live signal intelligence features, and engagement with clinicians, researchers, hospital systems, physician networks, and strategic advisors. The updates frame AimwellBio's work around healthcare RegTech, AI-output verification, clinical information validation, and structured intelligence mapping.
Aimwell Partners (OTCID:AIMN) brand AimwellBio reported progress on its FHIN (Federated Health Intelligence Network) healthcare intelligence framework and related AIMN infrastructure.
The company highlighted live demonstrations, onboarding feedback, expansion of focused intelligence layers, and continued development of the AIMN Verdict Layer and AIMN Atlas ecosystem.
AimwellBio (OTCID:AIMN) made its live Signal Intelligence feed publicly visible at aimwellbio.com/signals on May 6, 2026. The feed monitors 13 source streams in real time, archives verified signals (32 since activation in January), timestamps each alert, and assigns confidence scores and dispatch priority.
The company highlights industry frictions: an average 14-day awareness lag, a cited $12 million supply-chain exposure example, and an estimated $140 billion annual spend on outsourced intelligence.
Aimwell Partners (OTCID:AIMN) says early engagement with hospital systems, hospitalists, and clinical researchers generated strong interest in its Federated Health Intelligence Network (FHIN) founding cohort on May 4, 2026. The company plans accelerated FHIN enrollment, membership pursuit in scientific and medical associations, and further onboarding announcements as agreements are formalized.
AIMWELL Cortex is presented as a RegTech-enabled intelligence platform that verifies AI outputs, assigns confidence scores, and stores traceable source references for clinical and regulatory decision use.
Aimwell Partners (OTC:AIMN) launched AimwellBio, a verified healthcare intelligence layer aimed at reducing clinical reliance on unverified or AI‑generated outputs. The platform, powered by Aimwell Cortex, delivers continuously updated, source‑verified clinical insights, confidence scores, real‑time alerts, and proprietary verification protocols.
AimwellBio uses a Federated Health Intelligence Network (FHIN) to integrate distributed clinical input and continuous data verification into clinical workflows.
Aimwell Bio (OTC pink:AIMN) announced expansion of Federated Health Intelligence Network (FHIN) engagement with U.S. hospitals, physician networks and initial dialogue in Australia, marking FHIN's first international footprint.
The company says FHIN offers a human-verified, source-traceable verification layer to validate AI-assisted recommendations, reduce malpractice exposure, and support structured pilot deployments with select institutions.
Aimwell Bio (OTC Pink:AIMN) opened applications April 20, 2026 for a limited "Founding Cohort" of its Federated Health Intelligence Network (FHIN), a source-verified intelligence platform targeting a reported 38% AI hallucination rate in clinical content.
FHIN uses a Contribution-to-Credit model for experts to submit, validate, and earn credits; Aimwell says the network detects regulatory shifts within 72 hours and cites a $2.1M average malpractice settlement as part of the risk case for verified intelligence.
AimwellBio (OTC PINK:AIMN) launched AimwellBio, a verified intelligence platform for healthcare and biopharma that aims to catch AI-generated hallucinations before outputs reach patients, boards, or investors.
The core system, AIMWELL Cortex, monitors 13 source streams, traces outputs to sources, scores confidence, and applies a hallucination containment layer. Aimwell also opened a limited founding cohort for the Federated Health Intelligence Network (FHIN).
Market context: biopharma outsources ~$140 billion annually in intelligence, and RegTech is projected from $23B (2026) to $105B (2034), with healthcare RegTech growing ~19% annually.